remo in the inhbuitn of mitogen-and alloantigenthat can eliminate natural killer cells iNK), monocytes (Me), ced--O--r te limar ationro aotenithed and precursors of alloantigen-specific cytotoi T cells (pCTL) and untrea t a nd pevnhedloo nont from mouse spleen cell suspensions and from both mouse and of CTL from PCTL. The effects of these incubations were huapeierlbodTistamntevsitctBel, similar to those described in mice and humans. Addi-hua n rro T ratment a veo nt l tionally, in vitro CFU-GM growth from treated canir helper T cells, and murine erythroid and hematopojetic stem marrow was reduced, but could be regained when the cells (I114). In a murine histoincompatibie marrow transplant Lou-Leu-OMe.-treated marrow was cocultured with model (C57BL/6J-a*(C57BL/6XDBA/2)F,), treatment of donor either untreated autologous peripheral blood mononu-marrow and spleen cells with Leu-Leu-OMe resulted in succlear cells or monocyte-enriched PBMC but not with cessful donor marrow engraftment and the development of untreated monocyte-depleted PBMC. Six of seven dogs stable longterm hematopoietic chimerism without GVHD (14-conditioned with 920 cGy total-body irradiation on-16). The use of Leu-Leu-OMe to treat marrow may have grafte successfully after receiving autologous marrow adantages over currently used methods. The use of Leu-Leuthat was incubated with Leu-Leu-OMe prior to infusion. OMe is very simple, requiring but a single 15-min incubation. These cumulative results indicate that incubation with In addition, it appears that marrow iincubation with Leu-Leu. Leu-Leu-OMe is a feasible method to deplete canine marrows of aloreactive and cytotoxic T cells prior to OMe results in the elimination of the cells responsible for acute Q r% transplantation. K--Wr 45%e, 0fk "€ ::o , I GVHD while at the same time preserving hematopoietic stem C Nr\x \ Lf . ,%. cells needed for engraftment and the cells required for immune -,'he success of allogeneic marrow transplantation 'as treat. reconstitution (15, 16). ment for malignant and nonmalignant hematopoietic diseases
We and others have used dogs as a large, outbred animal hasbeen restricted by the berious complications of graft-versusmodel for us in experimental marrow transplantation (17, If). host disease 4QU Experiments in a variety of mammalian The present studies were undertaken to determine whether the marrow transplant models have shown that removal of mature incubation of canine marrow and peripheral blood cells with T cells from donor marrow permits engraftment without the Leu-Leu-OMe would yield alterations of in vitro cellular imd._elopme1t of GVHD 4
Based on these and similar mune function comparable to those described in human and observations, studia--ve been carried out to evaluate the murine cells and to investigate the effects of marrow incubation effects of T cell depletion prior to allogeneic marrow transplanwith Leu-Leu-OMe on'early hematopoietic progenitors and tation in humans. Most studies have employed marrow treat-stem cells assayed for both in vitro and in vivo function. ments with anti-T cell ronoclonal antibodies plus complement MATERIALS AND METHODS or with soybean agglutinin followed by E rosette formation and density gradient centrifugation (7-Y). In general, removal of T Dogs. Beagles, hounds, and mixed breed hounds, obtained from commercial vendors in Washington and Virginia or raised at the Fred cells has been associated with a marked decrease in both the Hthno acrRsac etr(HR) eedwre n 'Hutchinson Cancer Research Center tFHCRC), wer dwormed and incidence and severity of GVHD. However, the use of T cellvaccinated against distemper, hepatitis, leptoepirosis, and parvoviru depleted marrow has also been associated with an increased before use in this study. All dogs were at least iil monthe of a and incidence of marrow graft rejection (10).
were maintained at the FHCRC. canine kennel facilities per guidelines stipulAted by die National Academy of Sciences-National Research This work was supported ay Grants CA31787 and CAi8105 from Council. The research protocol was approved by the Internal Animal the National Cancer Institute, National institutes of Health, DHHS, Cas and Use Committee at the Fred Hutchinson Cancer Research and by contrr _ DNA 001-86-C-0192 of the Defense Nuclear Agency, Center. Armed Forces Radiobiology Research Institute. Views presented ar Medium Wsymouth's MB752/1 medium (FHCRC media prepara. those of the authors; no endorsement by the Defense Nuclear Agency tion facility), supplemented with 0.1 mM nonessential amino acids and has been given or should be inferred. Research was conducted accordi 100 U/ml penicillin and 100 jg/ml streptomycin (all from GIBCO), to the principles enunciated in the "Guide for the Care lation counting as previously described (23) with minor modifications. Cell preparation. Peripheral blood mononuclear cells were obtained The 10' Leti-Leti-OMe-treoated or untreated csirponder and 10' irradi-, by the centrifugation of heparinized venous whole blood (diluted 1:2 ated (2300 rada) untreated, atimulator PBMC were cocultured in a with medium) 0-er Ficoll-Hypeque density gradients (Sp. denaity final volume of 200,ul M-NPS/20% per wall. Mitogen stimulation was 1.074) so previously described (19). Bone marrow cells (BMC) for in aaaeased by adding either 375 pg/ul PHA (DIFCO, Detroit Ml), 200 vitro assays were obtained by syringe aspiration from the bumeral heed mg/ml Con A. (Calbiocheom, Sao Diego CA), or 200 pg/inl PWM of an anesthetized dog., The marrow was diluted 1:2 with medium and (GIECO, Grand Island, NY) to 10'treted or untreated responder cells' overlayed onto Ficoll-Hypaque density gradients, for centrifugation in afinal volume of 200 #1o(M-NPS/20%. All cultures were established (1000 x g), following which the interface cells were waahed once with in triplicate in microtiter plates, (Costar No. 3799, Cambridge MA) for hemolytic buffer and twice with medium. The PBMC and marrow cells 7 days at 37*C, 7% C%., in a humidified incubator. were resuspended into medium for cell counte and viability assesasment Bulk MIX (B-MIX) and ceil-mediated lymphodyuis assays. Bulk wing the trypan-blue exclusion techniqtw.
MLCs were established using estae untreated or Leui-Leu-OMeMonocyte-enriched cells *eere obtained by treating PBMC with the treated PBMC or marrow cells em relpondars, and untreated, irradiated anticanine murine monoclonal antibody Dly 6 (20) as follows. 300X 10?
PBMC as stimulators, to generate ClTL for CML assays, as previously, *PBMC were incubated for 30 min at room temperature in 30 ml of described (19), with modificatiam. CTL were derived from these cul-1:100 diluted Dly 6 (ascites containing antibody), and then an equal tures to form two CML assay gps:g (1) responder PBMC or marrow volume of 1:2 diluted rabbit serum complement (Pei Freeze, tLogera.
cells treated with Leu-LAu-OM@ or MeOH on day 0 prior to mixing AR) was added for an additional 60 min. The cells ware washed once with irradiated stimulator PBMC in B-MLC (day 0); and (2) Leu-Leuwith medium, reauspunded in 30 ml of 1:3 diluted rabbit serum comple-0M* or MeOH treatment of 7-day B-MLC generated CTL (day 7). ment, and incubated agan for 60 min. After washing twice An medium, CTIA were mixed at a 50:1 effectastarget ratio, with "Cr-labeled "Na theme cell suspensions contained 61±8% (SEM) viable mo'.ocytes, 16± Cr0. (300-500 pCi/mI, NEN, ilmiington DE) Con A-stimulated 3% lymphocytes, and 23±9% granulocytes, primarily eceinophila.
PBMC targets. Cultures of PBMC to be used for targets in the CML Monocyte-depleted PBMC were obtained by first passing PBMC meaya were established on the sam day of B-MLC, and stimulated over nylon-woo columns as previously described (21), and than trans-with Con A on day 4 of cultusa The 4-hr "Cr release msay was ferring 30x10'P nylon'-woo-nonadherent (NWNA) cells in 10 ml] of performed as previously described (19). The mean spontansous/maxi. medium, containing 5% fetal calf serum, into plastic petri dishei, mum "Cr release ratio was 16±1% (:t SEM), while maximum relese/ (Falcon No. 3003, Lincoln Park, NJ) for 2 hr incubation at 37C, 71% total "Cr incorporation was 90±2% for targets used in this senis of C%. This depleivion technique yielded approximately 956±1% lymphoid CML msays. cells with greater than 90% viability and les than 3% monocytes as Proliferation of treated oe untreted responder PBMC or marrow determined by morphologic aseessment of Wnight-stained cytoepin cella in 7-day B-MLC wm eas red by distributing 20 0 -ol aliquots preparations,. ftrm each B-MLC flask into triplikmte microcultur' wells and labeling Preparewion; o( Letu-Leui-Oft. The Leu-Leu-OMo was synthesized for 7 hr with ['Htbymidins. C.e harvest and liquid ecintillation from L-leuiyI.L-leucin* (Sigma Chemical Co, St Louis. MO) as previ-counting were perforined as desibe 'for MLC (23) . ously described (11). Qualitative aseessment of Leu-Leu-OMe purity Natural kidrr cell (NK) assys. Lati-Lim-OMe or MeOH treated or was obtained by thin-layer chromatography (TLC) (22) . Briefly, 5 A of untreated PE MC arid marrowcellsawremssayed fo. NK activity against 5xl0-' M solutioni of L-leucine methyl esfter (Leu-OMs) (dissolved in a "Cr-labeled canine thyroid adenacarcinoma cell line
hr asay with the pe-coatal of 1"Cr release calculated as previously (both dissolved with heat and stirring in absolute miethanol containing described (24).
N HCI), and the synthesized l~u-Leu-OMe ware applied to ~d
In vitro marrow culture@ *o Cnf'-GM srowt#. Lou-Leu-OMe sOW coated TLC plates (250 i&M, 10X20-cm, HPTLC Kieselgel 60 (Merck). MeOH treated and untreated marrow cells were tested for in vitro Darmstadt, West Germany), and quickly driod under a stream of warm .ematopoletic progenitor growth inagan agar-based colony formation air. Thie plates were develoljM for 2.5-hr in an einclooed, equilibrated msay that utilises poetendotoxia dog serum (PEDS) as the source of system containing the following mixture of reagent grads solvents:
cotony-stimulating factor (25). Growth of granulocyte/macrophage colchloroform, absolute methanol anid acetic acid at volume ratios of onies (CFU-GM) was assayed is cultures containing 10' or Ux100' 19-.0.6:12.5. respectively. The migrations of the four compounds ware treated or untreated maro cells only, and in cultures in which marrow visuialized by applying an aeroeol spray of 0.2% ninhydrin in ethanol -lHs waen cocultured with citherU10' utologous PBMC, Mo-enriched and then placing the plates in a 60*C oven for 30 min 11, values (the or Mao-depleted PBMC, or teAu-Leu-OMe treated PBMC (invubated ratio of the distance the compound travels to the distance the solvent with 1000 pM Leti-Leui-O~eP. Cultures were incubated in triplicate for front travels) were calculated, in order to ases the resultant migra-10 days in a 37*C, 7% CO, humidified incubsar and GFU-GM colonies tione, according to the fhil-"ing formula (22) :
ware enumerated as previously dsecribd (25). distncetra ledby ompundAutologous mirrou transpliwuetion. Marrow for autokogoue transdistace trvele by cmpoun *'lntation was obtained by a vicism pump aspiration procedure (26), distance traveled by solvent front pirocesred over a Facoll-Hypaqusi desity gradient Prnd incubated with Lou-Leu-OM*. All recipients were conditioned with 920 cGy total-body Lau-Leu-OMe was stored at -20C in absolute methanol and, based irradiation delivered as a single exposure from two oppoeing 'Co on repeated TLC analysis, was stable for at least three months.
sources at 7.0 cGy/min (20) . The recipients were infused with treated
Incubation of PBMC or morrow cells with Leu-Leu-OMe. Equ-il eutologous marrow within 3 hr of TBl. Supportive care pre-and volumes of PBMC or marrow cell suspensions and Lou-Leu-OMe at poattransplsntstion with antibiotics, i.v. fluids, and whole-blood transthe indicated final concentrations were incubated for 15 min at room fusions, was given as previously ecribed (27). In addition. recipients temperattrre. Cells for in vitro studies ware washed twice and resus-were given oral antibiotics (Noomycia sulfate and ,olyinyxin B sulfate) pended in medium. Marrow cells used for itutologous infusion ware daily for riva days before TBI and poettransplant until the granujlocyte incubated at cell concentrations of 20X10'/ml i42 Leu-Leu-OM* solu-count reached 500/mm'. (Fig. 1) . In all assayq there was a Leu-Leu-OMe Da i0 0, dose-dependent reduction in the proliferative response such 250 that virtually no blastogenesis was observed after incubation Dy 500 PBMC with 1000 &M Leu-Leu-OMe. 
1000C
, PBMC marrow cells witi 0.5% MeOH in PBS had no effect on the alioproliferative response in B-MLC (data not shown). ity against "'Cr-labeled alloantigen-specific Con A-stimulated 8 so-PBMC (Fig. 2) . These results indicated that the generation of N CTL from precursors is sensitive to incubation with Leu-LeuOMe. The effect of Leu-Leu-OMe incubatioii on CTL already 250 Ft8400 generated in 7-day bulk MLC (day 7 treatment) was also 20 1 evaluated. This treatment eliminated antigen-specific cytolytic , 8o activity (Fig. 2) FIGURE 3 . Leu-Leu.OMe treatment of PBMC and BMC eliminates activity, in a dose-dependent manner, was seen after incubation NK cytolytic activity. The ordinate indicates mean percentage of Cr of PBMC or marrow cells with Leu-Leu-OMe, and NK activity release ± SEM from CTAC at three different effector:target (E:T) was essentially eliminated after treatment with 1300 pM Leuratios. For this series of assays, the mean spontaneous/maximum SCr Leu-OMe (Fig. 3) .
release ratio was 23±1 % (± SEM) and the maximum release/total "Cr In vitro CFU-GM colony growth reduction by Leu-Leu-OMe inc ._",ration ratio was 65±7%.
TRANSPLANTATION
VoL 46, No. 5 treatment of marrow cells. There was a marked reduction in C521, but the treated marrow cells of C580 did not clump and CFU-GM colony growth obtained from marrow cells incubated this dog survived with rapid eagraftment. Dog BB8701 had to withi varying concentrations of Leu-Leu-OMe (Table 1) . Mini-be euthanized on day 19 poetzrsnsplant due to an accidental, mal CFU-GM growth was observed with 10' Leu-Leu-OMe severe, foot injury that failed to respond to treatment, but did treated marrow cels per plate were cultured. There was some show evidence of engraftment nindicated by a rise in WBC recovery of CFU-GM growth when the cell number was in-and the marrow cellularity at atopsy. creased to 3X1O'~ treated marrow cells per plate, but only to a level that was approximately 25% of that observed with 3X I0, DISCUSSION untreated marrow cells. Addition of either untreated, autolThiele and Lipsky have demonstrated that exposure of mouse ogous PBMC or Me-enriched autologous PBMC increased spleen cels or humnan peripheral blood leukocytes to Leu-Leu-CFU-GM growth, but not to the levels observedwith untreated OMe depletes these populations of monocytes, NK cells, and marrow cells in similar cocultures. The addition of Mo-depleted cytotoxic lymphocytes at both the precursor and effector stages or Leu-Lieu-OlMe treated autologous PBMC to treaed marrow of differentiation, without apparently affecting other cell popcells did not augment growth.
ulations (I11-13) . They futhet showed that incubation of mixVie effect of incubating marrow cells with Leu-Leu-OWe on turns of murine marrow and spleen cells with Leu-Leu-OMe aastologous marrow engrrfr~ment. Six of the seven dogs given did not interfere with engraftlpent and could, in certain circumLeu-Leu-OMe treated autologous marrow engrafted and did so stances, prevent GVHD (14-16). In the studies presented here, with kinetics similar. to those seen in recipients of untreated we found that canine peripheral blood and marrow cells behave autologous marrow (Table 2 and Fig. Q) . Platelet counts re-similarly following exposure to Leu-Leu-OMe with the elimiturned' to normal levels between 20 to 30 days posttrangplant. nation of fuinctional monocyte., NK cells, and alloantigert Dog C521 did not survive past day 20 poettransplant. After sensitized CTL and inhibited the development of CTL from Leu-Leu-OMe incubation, the marrow cells from this dog were pCTL. Further, we found that incubation of marrow cells with clumped and had only 20% viability, resulting in the infusion Leu-Leu-OMe (even at very high doses) did not inhibit autolof a very low marrow cell dose. The marrow from C580 was ogous engraftment in recipients conditioned with 920 cGy TBI. incubated with the same concentration of Leu-LeAu-01Ole as These studies also demonstrated that the treatment of canine TARLE 1. In vitro CFU-GM colony growth from marrow cells incubated with varying concuure a of Leu-Leu.OM. Reprenented are mesn values ± SEM, obtained from multiple experiments in which triplicate CFU-GU cultures were established for eaich paramettr teeted., I All cocultures employed autologous cells. The limit,d yield of Me prevented coculture with all concentrations of Leu-LeuOMe tested. There was no CFU-GM growth when untreated PBMC (between 10' to 6X l(Y/mI) were cultured without marrow calls& 'The concentration of marrow cells treated was constant at 2OX 10/ml. 'Autologous marrow spiration. BMC treatment, and infusion on ame day as 920 cC~y THI to recipient jBMT: bone marrow transplant). '2')X10' BMC/ml trested with Leu-Leu-OMe. WVability of bone marrow cells infused determined by trypan-blue stain exclusion technique. Sodium pentothal injection for euthanasia at end of study. 'The Leu-Leu-OMe-treated sutologous marrow was frowen and stored at -80T' for one week prior to reinfinion. The procedure for marrcw cryupreservation was'as described (26).
CFIJ-GM colonies obtained from CFU-C cultnuss'
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RAFF bone marrow with monoclonal anti-T-cell antibody and comple-
